InvestorsHub Logo
Followers 42
Posts 4850
Boards Moderated 0
Alias Born 08/06/2012

Re: Uboat post# 76406

Friday, 10/13/2017 3:18:48 PM

Friday, October 13, 2017 3:18:48 PM

Post# of 144814
They sure did!

Quote:
“TGen receives $2.5 million SU2C grant for new pancreatic cancer clinical trial”

I wonder why Dr. Von Hof didn’t pick ciab. Unlike investors he has no faith I guess.

Dr. Daniel Von Hoff, TGen Distinguished Professor and Physician-In-Chief, will lead a pancreatic cancer clinical trial that will pair an immunotherapy drug called pembrolizumab (trademarked as Keytruda®), with a Vitamin D Receptor (VDR) agonist called paricalcitol (trademarked as Zemplar®).

https://www.eurekalert.org/pub_releases/2017-10/ttgr-tr101217.php

Disclosure: I am involved in and support the SEC whistleblower program, I may be rewarded cash for information that leads to the successful enforcement by the SEC of a federal court or administrative action of 1m+.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News